- Trials with a EudraCT protocol (2,069)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
2,069 result(s) found for: Drug testing.
Displaying page 6 of 104.
EudraCT Number: 2015-004024-54 | Sponsor Protocol Number: GS-US-380-1489 | Start Date*: 2016-02-18 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretrovira... | |||||||||||||
Medical condition: Human Immunodeficiency Virus (HIV-1) Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) DE (Completed) ES (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004588-30 | Sponsor Protocol Number: TED-C13-003 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:NPS Pharmaceuticals, Inc. | |||||||||||||
Full Title: A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year through 17 Years, with Short Bowel Syndrome who are Dependent on Parenteral Support | |||||||||||||
Medical condition: Short Bowel Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005544-10 | Sponsor Protocol Number: NIHRCDF | Start Date*: 2012-04-10 | |||||||||||
Sponsor Name:Imperial College London | |||||||||||||
Full Title: Improving Inhaler Treatment and Small Airways Assessment in Chronic Obstructive Pulmonary Disease | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000346-19 | Sponsor Protocol Number: HP-CD-CL-2003 | Start Date*: 2018-06-04 | |||||||||||
Sponsor Name:Herantis Pharma Plc | |||||||||||||
Full Title: A Randomised, Double-Blind, Multi-centre, Active Treatment, Extension and Safety Study for Patients with Idiopathic Parkinson’s Disease (PD) Who Previously Completed the CDNF/DDS Main Study HP-CD-C... | |||||||||||||
Medical condition: Idiopathic Parkinson's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004178-24 | Sponsor Protocol Number: RP-OSV-02-D | Start Date*: 2013-12-27 |
Sponsor Name:Fresenius Medical Care Deutschland GmbH | ||
Full Title: Study to investigate the therapeutic equivalence of OsvaRen® tablets and OsvaRen® granules | ||
Medical condition: Hyperphosphataemia in end stage renal failure patients on extracorporeal renal replacement therapy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-001218-26 | Sponsor Protocol Number: TRO19622 CL E Q 1204-1 | Start Date*: 2008-06-19 | |||||||||||
Sponsor Name:TROPHOS SA | |||||||||||||
Full Title: A double blind, placebo controlled study of the effect of 330mg QD of TRO19622 in the treatment of Chemotherapy Induced Peripheral Neuropathy. | |||||||||||||
Medical condition: Symptoms of chemotherapy induced peripheral neuropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-005101-29 | Sponsor Protocol Number: KCH-MDS-04-1.0 | Start Date*: 2005-02-24 | |||||||||||
Sponsor Name:King's College Hospital NHS Foundation Trust [...] | |||||||||||||
Full Title: THE EFFICACY AND SAFETY OF LENALIDOMIDE (Revlimid®) MONOTHERAPY IN RED BLOOD CELL TRANSFUSION DEPENDENT SUBJECTS WITH MYELODYSPLASTIC SYNDROME ASSOCIATED WITH A DEL (5q) CYTOGENETIC ABNORMALITY | |||||||||||||
Medical condition: Myelodysplastic Syndrome (MDS) associated with a Del (5q) cytogenetic abnormality | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001139-38 | Sponsor Protocol Number: 3475-689 | Start Date*: 2018-02-02 | |||||||||||
Sponsor Name:Merck Sharp & Dohme LLC | |||||||||||||
Full Title: A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for StageIII-IVA Resectable Locoregionally Ad... | |||||||||||||
Medical condition: Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) PT (Trial now transitioned) ES (Restarted) HU (Trial now transitioned) GB (GB - no longer in EU/EEA) PL (Trial now transitioned) FR (Trial now transitioned) AT (Trial now transitioned) IE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003988-10 | Sponsor Protocol Number: GS-US-380-1490 | Start Date*: 2016-02-18 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infec... | |||||||||||||
Medical condition: Human Immunodeficiency Virus (HIV-1) Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) DE (Completed) ES (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001684-21 | Sponsor Protocol Number: NV1205-009 | Start Date*: 2018-04-20 |
Sponsor Name:Neurov Acquisition LLC | ||
Full Title: Phase I/II, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of NV1205 in Pediatric Male Subjects with Childhood Cerebral Adrenoleukodystrophy (CCALD) | ||
Medical condition: Childhood Cerebral Adrenoleukodystrophy (CCALD) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male | |
Trial protocol: GB (Prematurely Ended) FR (Ongoing) | ||
Trial results: View results |
EudraCT Number: 2005-003617-33 | Sponsor Protocol Number: 03-2005 | Start Date*: Information not available in EudraCT |
Sponsor Name:Charité | ||
Full Title: A Randomised Cross-Over Study to Explore the Pathophysiological Mechanisms Involved in the Treatment of Actinic Keratoses with Solaraze | ||
Medical condition: actinic keratosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-001331-26 | Sponsor Protocol Number: PROLIFIC2020 | Start Date*: 2020-04-14 | |||||||||||
Sponsor Name:Cambridge University Hospitals NHS Foundation Trust | |||||||||||||
Full Title: ChemoPROphyLaxIs For covId-19 infeCtious disease (the PROLIFIC trial) | |||||||||||||
Medical condition: Coronavirus disease 2019 (COVID-19) caused by the infection, SARS-CoV-2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-005476-32 | Sponsor Protocol Number: VR004/008 | Start Date*: 2006-02-02 |
Sponsor Name:Vectura Group plc | ||
Full Title: A Phase IIb, Randomised, Double-Blind, Placebo Controlled, Dose Finding Study Assessing the Haemodynamic Safety and "At Home" Efficacy of Inhaled VR004 in patients with Erectile Dysfunction (ED). | ||
Medical condition: Erectile dysfunction | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-005086-20 | Sponsor Protocol Number: CHDR1117 | Start Date*: 2011-11-22 |
Sponsor Name:Centre for Human Drug Research (CHDR) | ||
Full Title: Effects of paracetamol on nociception in adolescents. | ||
Medical condition: Nociceptive pain (disorders) | ||
Disease: | ||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2022-002520-13 | Sponsor Protocol Number: 251602 | Start Date*: 2022-07-18 |
Sponsor Name:Baxalta Innovations GmbH | ||
Full Title: Phase IV Multi-center, Prospective, Interventional, Post-marketing Study in Hemophilia B Patients in India receiving RIXUBIS as On-demand or Prophylaxis Under Standard Clinical Practice | ||
Medical condition: Hemophilia B | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2018-004926-26 | Sponsor Protocol Number: PRV-031-001 | Start Date*: 2019-11-21 | |||||||||||
Sponsor Name:Provention Bio, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Multinational, Placebo-Controlled Study to Evaluate Efficacy and Safety of Teplizumab (PRV-031), a Humanized, FcR Non-Binding, anti-CD3 Monoclonal Antibody, in ... | |||||||||||||
Medical condition: Type 1 Diabetes (T1D) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) PL (Completed) DE (Completed) FR (Completed) FI (Ongoing) BE (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001817-35 | Sponsor Protocol Number: 111958 | Start Date*: 2021-08-04 |
Sponsor Name:Radboud University Medical Center | ||
Full Title: Suboxone (buprenorphine/naloxone) versus methadone opioid rotation in patients with escalated opioid use and chronic pain: a randomized trial. | ||
Medical condition: Opioid use disorder | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2012-005410-19 | Sponsor Protocol Number: HH-AT-001 | Start Date*: 2013-03-11 | |||||||||||
Sponsor Name:Jessaziekenhuis Hasselt | |||||||||||||
Full Title: Developing a Patient Model of Controlled, Radial Artery Access Site Bleeding for Deciding on Anticoagulation Reversal in Patients Treated by Systemic Anticoagulants. | |||||||||||||
Medical condition: With the novel oral anticoagulants, including EDOXABAN-DABIGATRANRIVAROXABAN- APIXABAN, we are entering a new era of anticoagulation for atrial fibrillation (AF) (and deep vein thrombosis). Neve... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003723-29 | Sponsor Protocol Number: JBT101-CF-002 | Start Date*: 2018-05-11 | |||||||||||
Sponsor Name:Corbus Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis | |||||||||||||
Medical condition: Cystic Fibrosis (CF) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) HU (Completed) SE (Completed) FR (Completed) PT (Completed) SK (Completed) AT (Completed) BE (Completed) ES (Completed) BG (Completed) NL (Completed) CZ (Completed) GR (Completed) PL (Completed) IT (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002761-63 | Sponsor Protocol Number: HPV-301 | Start Date*: 2018-04-16 | ||||||||||||||||
Sponsor Name:Inovio Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF VGX-3100 DELIVERED INTRAMUSCULARLY FOLLOWED BY ELECTROPORATION WITH CELLECTRA™ 5PSP FOR THE TREATMENT OF HPV-16 AND/OR H... | ||||||||||||||||||
Medical condition: HPV-16 AND/OR HPV-18 RELATED HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS (HSIL) OF THE CERVIX | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) LT (Completed) FI (Completed) DE (Completed) CZ (Prematurely Ended) ES (Completed) PT (Completed) PL (Completed) SK (Completed) BE (Completed) NL (Ongoing) EE (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
